Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: Anticancer Drugs. 2013 Oct;24(9):881–888. doi: 10.1097/CAD.0b013e32836442c6

Figure 2.

Figure 2

Effects of Mito-CP and 2-DG on proliferation of HepG2 and primary hepatocytes. A.HepG2 and primary hepatocytes cells were treated with increasing concentrations of Mito-CP, 2-DG, alone or in combinations for 24 hr. Proliferation results of average of two independent experiments are shown. HepG2 cell growth inhibition occurs significantly starting at a dose of 2 µM Mito-CP plus 2 mM 2-DG. Primary cells exhibit no reduction in cell viability. Individual treatment either Mito-CP or 2-DG did not affect the growth of HepG2 and primary hepatocytes. Analysis of ATP levels in HepG2 (B) and primary hepatocytes (C). Cells were treated with increasing concentrations of Mito-CP and 2-DG as indicated either alone or in combinations for 6 hr. and assayed for the levels of ATP. There is more than 50% depletion of ATP in HepG2 cells starting at treatment combinations of 2 µM Mito-CP and 2 mM 2-DG. However, the ATP levels in primary hepatocytes remain stable (>80%) at all treatment concentrations. Protein levels drop slightly at higher treatment concentrations in HepG2 cells but remain unaffected in primary hepatocytes.